

## iMM-Laço-HUB is recruiting a Postdoctoral Researcher under an Employment Contract Reference IMM/CT/79-2021

The iMM – Instituto de Medicina Molecular João Lobo Antunes (iMM), has very recently created the iMM-Laço-HUB that is a structure dedicated to the study of breast cancer to uncover novel modalities of treatments (more information at <http://immlaco.org>). The iMM-Laço-HUB now opens a call for the hiring of a Postdoctoral Researcher under an Unfixed-term contract, under the project “*Multi-Dimensional Cartography of the Breast Cancer Micro-Environment*”.

**Work Plan and Objectives:** In 2020, over 600 000 women died from breast cancer worldwide. Treatment of breast cancer, in particular metastatic, raises many challenges, due to resistance to available therapies. The development of novel, or combinatorial, treatments for breast cancer is an urgent unmet clinical need. The iMM-Laco-HUB objective is to create an unprecedented in depth multi-dimensional cartography of human breast cancer and to do so we will encompass spatial information about the genetic of the tumour cells, the local specific gene expression profile, the visualisation of the stroma architecture and localisation and phenotype of immune cells. In addition, a large body of evidence emerged supporting that microbiota may influence oncogenesis and its subsequent progression and response to anticancer therapy. Thus, we aim to evaluate *in situ* the tumour genetic and clonal distribution (using whole exome sequencing), the microbiota (using 16S rDNA sequencing) and the host stroma and immune responses (using RNA-sequencing, spatial transcriptomics and multiplexed imaging). The strength of iMM-Laco-HUB is to combine non-overlapping and complementary expertises (oncologists, pathologists, immunologists and computational biologists) to create a multi-dimensional atlas of the breast tumour tissue. We believe that this holistic approach will permit the reconstruction of micro-volumes at cellular resolution allowing visualisation of the crosstalks between tumour-immune/stroma cells and microbiota to unravel the major parameters and pathways that can be targeted to limit cancer progression and to determine the clinical course of the patients.

**What iMM seeks:** The iMM-Laço-HUB is looking for a Postdoctoral Researcher to join the Breast Cancer Lab coordinated by Dr Karine Serre. The Breast Cancer Lab acts in close collaboration with Professor Sergio Dias (iMM), Dr Nuno Morais (iMM) and Professor Luis Costa (iMM and Head of the Oncology department of Hospital de Santa Maria). The successful candidate must be a **highly motivated, pro-active, independent, gregarious and versatile** individual to join our multi-disciplinary team. He/She should be passionate about iMM-Laço-HUB’s missions of bringing hope to the women who are diagnosed with breast cancer and of being an instrumental member of a multi-disciplinary team dedicated to create a cellular and molecular map of the breast cancer microenvironment for the design of novel therapies and to support clinical decisions.

### The principal activities of the PostDoctoral Researcher will include:

- Manipulating biological human samples
- Determining the most appropriate protocols allowing subsequent selected studies
- Preparing the samples for whole exome sequencing, 16S rRNA gene sequencing and RNA-sequencing
- Performing multiplex imaging with confocal microscopy and the CODEX technology
- Participating in the conception of projects related with the iMM-Laço-HUB and in the writing of associated grant applications
- Participating in the integration and interpretation of the complex data
- Collaborating with and/or co-supervising computational biology MSc and PhD students
- Reporting results to a multidisciplinary team of oncologists, immunologists, molecular biologists and computational biologists and jointly interpreting them
- Participating in the outreach and science communication activities promoted by the iMM-Laço-HUB

### The following skills and qualifications are required:

- PhD in cancer biology, immuno-oncology, immunology will be highly valued
- High organization skills and strong work ethics (care, rigour, consistency, intellectual honesty)
- Aptitude to write and lead projects related with the iMM-Laço-HUB
- Willingness to work independently to design and perform experiments
- Proficiency in English, spoken and written, and excellent verbal and written communication skills

**What IMM offers:** IMM will offer outstanding working conditions, including a full-time contract, starting predictably in January 2022, and the possibility to work in the interface between hospital and biomedical institute on clinical and basic research. IMM will also offer access to state-of-the-art infrastructures, namely biobank, imaging unit and computational biologists partners.

**Working Conditions:** The employment contract has a predicted estimated duration of 12 months. Gross monthly salary is **2.134,73€**. The indicated amount will be subject to the mandatory taxes accordingly to Portuguese Labour Law.

**How to apply:** Please submit your detailed CV, motivation letter, PhD degree certificate and contacts of **3** references, from **25<sup>th</sup> of October 2021** until **19<sup>th</sup> of November 2021** through the email [imm-hr@medicina.ulisboa.pt](mailto:imm-hr@medicina.ulisboa.pt).

**Non-discrimination and equal access policy:** IMM promotes a non-discrimination and equal access policy, wherefore no candidate can be privileged, benefited, impaired or deprived of any rights whatsoever, or be exempt of any duties based on their ancestry, age, sex, sexual preference, marital status, family and economic conditions, instruction, origin or social conditions, genetic heritage, reduced work capacity, disability, chronic illness, nationality, ethnic origin or race, origin territory, language, religion, political or ideological convictions and union membership.

Pursuant to Decree-Law nr 29/2001 of 3<sup>rd</sup> February, disabled candidates shall be preferred in a situation of equal classification, and said preference supersedes any legal preferences. Candidates must declare, on their honour, their respective disability degree, type of disability and communication / expression means to be used during selection period on their application form, under the regulations above.

**Evaluation Criteria:** Applications will be evaluated by Sergio Dias, Nuno Morais and Karine Serre (all PhD's) in accordance with the following method:

- 1<sup>st</sup> Phase: Curricular evaluation: 45% and Motivation Letter: 20%
- 2<sup>nd</sup> Phase: Interview: 35%

**Results:** Both admitted and excluded candidates list and final classification list shall be posted at IMM website at <https://imm.medicina.ulisboa.pt/jobs/#results> and all admitted candidates will be notified by email.

**Preliminary Hearing and Final Decision Deadline:** Pursuant to article 121 of the Administrative Procedure Code, after notified, all candidates have 10 working days to respond. Panel's final decisions are pronounced within a period of 90 days, from application deadline.

#### Recent References:

Alpuim Costa D, Nobre JG, Batista MV, Ribeiro C, Calle C, Cortes A, Marhold M, Negreiros I, Borralho P, Brito M, Cortes J, Azambuja Braga S and Costa L. Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine. *Front. Microbiol.* 2021; 12. DOI: 10.3389/fmicb.2021.584332.

Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L and Casimiro S. Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer. *Oncotarget.* 2020; 11:1714–1728. DOI: 10.18632/oncotarget.27576.

Gregório AC, Lacerda M, Figueiredo P, Simões S, Dias S, Moreira JN. Meeting the needs of breast cancer: A nucleolin's perspective. *Crit. Rev. Oncol. Hematol.* 2018; 125:89–101. Available at: <https://doi.org/10.1016/j.critrevonc.2018.03.008>. DOI: 10.1016/j.critrevonc.2018.03.008.

Gomes CP, Nóbrega-Pereira S, Domingues-Silva B, Rebelo K, Alves-Vale C, Marinho SP, Carvalho T, Dias S and Bernardes Jesus B. An antisense transcript mediates MALAT1 response in human breast cancer. *BMC Cancer.* 2019; 19:1–11. DOI: 10.1186/s12885-019-5962-0.

Saraiva-Agostinho N, Barbosa-Morais NL. Interactive Alternative Splicing Analysis of Human Stem Cells Using psychomics. *Methods Mol Biol.* 2020; 2117:179–205.

Reis-Sobreiro M, Teixeira da Mota A, Jardim C, Serre K. Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. *Cells.* 2021; 10:2364. DOI: 10.3390/cells10092364.

**Lisbon, 25<sup>th</sup> of October 2021**

**NOTE: Deadline call was updated to 19<sup>th</sup> of November 2021**